Last reviewed · How we verify

NCT05955469

Comparison in New Cochlear Implanted Subjects of a Tonotopy-based Bimodal Fitting and a Conventional Fitting

Recruiting now NA Last updated 20 January 2026
What this trial tests

NA trial testing FS4 then TFS4 (cochlear implant) in Sensorineural Hearing Loss, Bilateral in 20 participants. Currently enrolling.

Timeline
5 November 2024
Primary endpoint
1 January 2027
1 January 2027

Quick facts

Lead sponsorMED-EL Elektromedizinische Geräte GesmbH
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposeother
Enrollment20
Start date5 November 2024
Primary completion1 January 2027
Estimated completion1 January 2027
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

MED-EL Elektromedizinische Geräte GesmbH — full company profile →

Who can join

18 and older, any sex, with Sensorineural Hearing Loss, Bilateral or Bilateral Hearing Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Main objective: For a bimodal fitting (hearing aid (HA) + cochlear implant (CI)): Comparison of a tonotopy based fitting strategy (TFS4) to a default fitting strategy (FS4) for the speech recognition in noise. Secondary objectives: Comparison of TFS4 to FS4 for speech recognition in quiet. Comparison of TFS4 to FS4 for the auditory skills experienced by the subject.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sensorineural Hearing Loss, Bilateral

Currently open trials in the same condition.

Other MED-EL Elektromedizinische Geräte GesmbH trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05955469.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing